Skip to content

CareDx CDNA Additional Paid-In Capital

Additional Paid-In Capital at other companies

Natera, Inc. logo
Natera, Inc.NTRA
$4.64B+19.6%
NeoGenomics logo
NeoGenomicsNEO
$1.28B+3.2%
Personalis, Inc. logo
Personalis, Inc.PSNL
$916.12M+18.5%
GeneDx Holdings logo
GeneDx HoldingsWGS
$1.69B+4.6%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$490.5M+3.1%
Veracyte logo
VeracyteVCYT
$1.7B+2.5%

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's additional paid-in capital?
CareDx (CDNA) reported additional paid-in capital of $1.05B in Q1 2026.
How has CareDx's additional paid-in capital changed year-over-year?
CareDx's additional paid-in capital increased by 2.9% year-over-year, from $1.02B to $1.05B.
What is the long-term trend for CareDx's additional paid-in capital?
Over 5 years (2020 to 2025), CareDx's additional paid-in capital has grown at a 10.5% compound annual growth rate (CAGR), from $632.25M to $1.04B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.